Skip to main content
Clinical Trials/EUCTR2013-000330-35-AT
EUCTR2013-000330-35-AT
Active, not recruiting
Phase 1

Effects of Linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes - Linagliptin and endothelial function

Medizinische Universität Graz0 sites50 target enrollmentApril 23, 2013

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Medizinische Universität Graz
Enrollment
50
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 23, 2013
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- Age 40\-75
  • \- Early diabetes (postchallenge diabetes (2h glucose \>200 mg/dl or type 2 diabetes treated with diet only or on a stable dose of metformin monotherapy)
  • \- Coronary atherosclerosis (diagnosed via coronary angiography or coronary computer tomography)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 35
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 15

Exclusion Criteria

  • \- Acute coronary syndrome or cerebrovascular event within the previous 4 weeks
  • \-BMI \> 35 kg/m2
  • \- Serum creatinine \> 2\.5 mg/dl
  • \- AST/ALT \> 3x upper limit of normal
  • \- HbA1c \>9\.0% (\>75 mmol/mol)
  • \- Heart failure \> NYHA class II
  • \- Uncontrolled hypertension (blood pressure \> 165 / 100 mmHg)
  • \- Treatment with orally administered steroids
  • \- New onset statin or ACE\-inhibitor within the previous 6 weeks
  • \- Known Malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials